| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Verona Pharma gets green light for COVID treatment trial
StockMarketWire.com
|
Biopharmaceuticals company Verona Pharma reported an operating loss of $46.2 million for the first nine months of 2020 as it began work on a potential treatment for COVID-19.
This compared to a $42.7 million loss in the same period last year. However, the company raised $200 million from a private placement, bringing its net cash position to $202 million.
In July, Verona received a notice to proceed from the US Food and Drug Administration for a trial of the company's pMDI ensifentrine drug for the treatment of patients hospitalised with COVID-19. The study began in September.
Verona has also commenced trials of the same drug for the treatment of patients with chronic obstructive pulmonary disease.
At 9:31am: (LON:VRP) Verona Pharma PLC share price was +3p at 55p
Story provided by StockMarketWire.com
|
|
|
|
|
|
